{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T23:48:14Z","timestamp":1768866494943,"version":"3.49.0"},"reference-count":53,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T00:00:00Z","timestamp":1479945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Both male\/female patients with Fabry disease (FD) may receive enzyme replacement therapy (ERT). Previously published analyses of the Fabry Outcome Survey (FOS; Shire-sponsored) database suggested gender differences in timing of ERT initiation. We assessed alignment of criteria for ERT initiation in the Spanish adult population included in FOS with recommendations of a Spanish national consensus. This retrospective analysis examined baseline clinical data of 88 adults (49 females) enrolled in the FOS database up to August 2014. Thirty-five (39.8%) patients were not receiving ERT: five (12.8%) males and 30 (61.2%) females. Baseline disease severity on the FOS-derived Mainz Severity Score Index was lower in untreated males (median (interquartile range), 0.0 (0.0\u20131.0)) than treated males (TM; 15.0 (7.5\u201326.5)), and was similar in untreated and treated females. The percentage of untreated females with at least one criterion for treatment initiation was 76.7% versus 100.0% of treated females (p = 0.0340) and 97.1% (p = 0.0210) of TM. In discordance with Spanish consensus recommendations, a substantial number of females with evidence of FD who might benefit from ERT have not yet initiated treatment. These results suggest unequal gender perceptions with respect to ERT initiation in Spain.<\/jats:p>","DOI":"10.3390\/ijms17121965","type":"journal-article","created":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T10:19:15Z","timestamp":1479982755000},"page":"1965","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Gender Differences in the Application of Spanish Criteria for Initiation of Enzyme Replacement Therapy for Fabry Disease in the Fabry Outcome Survey"],"prefix":"10.3390","volume":"17","author":[{"given":"Miguel-\u00c1ngel","family":"Barba-Romero","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Albacete University Hospital, Castilla-La Mancha University, 37 Hermanos Falc\u00f3 St., 02006 Albacete, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillem","family":"Pintos-Morell","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Germans Trias i Pujol University Hospital and Research Institute (IGTP), Universitat Aut\u00f2noma de Barcelona, 08916 Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2016,11,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cccn.2004.10.019","article-title":"Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers","volume":"353","author":"Linthorst","year":"2005","journal-title":"Clin. Chim. Acta"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/qjmed\/hcq117","article-title":"Fabry disease: A review of current management strategies","volume":"103","author":"Mehta","year":"2010","journal-title":"QJM"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","article-title":"Enzyme replacement therapy with agalsidase alfa in patients with Fabry\u2019s disease: An analysis of registry data","volume":"374","author":"Mehta","year":"2009","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1651-2227.2005.tb02106.x","article-title":"Natural history of the cerebrovascular complications of Fabry disease","volume":"94","author":"Mehta","year":"2005","journal-title":"Acta Paediatr."},{"key":"ref_6","first-page":"21","article-title":"Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis","volume":"3","author":"Beck","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.ki.5000208","article-title":"Clinical benefit of enzyme replacement therapy in Fabry disease","volume":"69","author":"Breunig","year":"2006","journal-title":"Kidney Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: A randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1651-2227.2007.00029.x","article-title":"Enzyme replacement therapy with agalsidase alfa in children with Fabry disease","volume":"96","author":"Ramaswami","year":"2007","journal-title":"Acta Paediatr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1542\/peds.2005-2895","article-title":"Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease","volume":"118","author":"Ries","year":"2006","journal-title":"Pediatrics"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson\u2013Fabry disease: A randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.clinthera.2009.09.008","article-title":"Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: A 12- to 36-month, retrospective, blinded echocardiographic pooled analysis","volume":"31","author":"Kampmann","year":"2009","journal-title":"Clin. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ymgme.2012.05.011","article-title":"Enzyme replacement therapy improves cardiac features and severity of Fabry disease","volume":"107","author":"Motwani","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_14","first-page":"77","article-title":"Enzyme replacement therapy and renal function in 201 patients with Fabry disease","volume":"66","author":"Schwarting","year":"2006","journal-title":"Clin. Nephrol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","article-title":"Agalsidase alfa and kidney dysfunction in Fabry disease","volume":"20","author":"West","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmg.2008.065904","article-title":"Natural course of Fabry disease: Changing pattern of causes of death in FOS \u2013 Fabry Outcome Survey","volume":"46","author":"Mehta","year":"2009","journal-title":"J. Med. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1023\/B:BOLI.0000005658.14563.77","article-title":"Enzyme replacement therapy in heterozygous females with Fabry disease: Results of a phase IIIB study","volume":"26","author":"Baehner","year":"2003","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/GIM.0b013e3181a23bec","article-title":"A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease","volume":"11","author":"Whybra","year":"2009","journal-title":"Genet. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/GIM.0b013e3181f13a4a","article-title":"Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: Findings from the Fabry Registry","volume":"12","author":"Watt","year":"2010","journal-title":"Genet. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ymgme.2011.03.022","article-title":"Response of women with Fabry disease to enzyme replacement therapy: Comparison with men, using data from FOS\u2014The Fabry Outcome Survey","volume":"103","author":"Hughes","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.jpeds.2009.07.003","article-title":"Guidelines to diagnosis and monitoring of Fabry disease and review of treatment experiences","volume":"155","author":"Martins","year":"2009","journal-title":"J. Pediatr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: The European Fabry Working Group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_24","unstructured":"GU\u00cdA CL\u00cdNICA Para el Estudio y Tratamiento de la Enfermedad de Fabry. Available online: http:\/\/www.sochipe.cl\/subidos\/catalogo1\/docs\/er_973a.pdf."},{"key":"ref_25","first-page":"178","article-title":"Consensus for the study and treatment of Fabry disease. GETER Foundation","volume":"137","year":"2011","journal-title":"Med. Clin. (Barc.)"},{"key":"ref_26","first-page":"379","article-title":"Comparison of patients from a Spanish Registry of Fabry disease in two periods","volume":"139","year":"2012","journal-title":"Med. Clin. (Barc.)"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/j.1742-1241.2011.02695.x","article-title":"Fabry disease in Spain: Description of Spanish patients and a comparison with other European countries using data from the Fabry Outcome Survey (FOS)","volume":"65","year":"2011","journal-title":"Int. J. Clin. Pract."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","article-title":"Nephropathy in males and females with Fabry disease: Cross-sectional description of patients before treatment with enzyme replacement therapy","volume":"23","author":"Ortiz","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jacc.2010.11.018","article-title":"Cardiovascular events in patients with Fabry disease: Natural history data from the Fabry Registry","volume":"57","author":"Patel","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","article-title":"Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life","volume":"9","author":"Wang","year":"2007","journal-title":"Genet. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","article-title":"Prognostic indicators of renal disease progression in adults with Fabry disease: Natural history data from the Fabry Registry","volume":"5","author":"Wanner","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","article-title":"Renal outcomes of agalsidase beta treatment for Fabry disease: Role of proteinuria and timing of treatment initiation","volume":"27","author":"Warnock","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s10897-008-9179-7","article-title":"Disease rarity, carrier status, and gender: A triple disadvantage for women with Fabry disease","volume":"17","author":"Gibas","year":"2008","journal-title":"J. Genet. Couns."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jmg.2005.036327","article-title":"Natural history of Fabry disease in females in the Fabry Outcome Survey","volume":"43","author":"Deegan","year":"2006","journal-title":"J. Med. Genet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2217\/WHE.12.22","article-title":"Disparities in heart failure and other cardiovascular diseases among women","volume":"8","author":"McSweeney","year":"2012","journal-title":"Women Health (Lond. Engl.)"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1159\/000320389","article-title":"Gender differences in chronic kidney disease: Underpinnings and therapeutic implications","volume":"33","author":"Carrero","year":"2010","journal-title":"Kidney Blood Press. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/cge.12386","article-title":"The kidney in Fabry's disease","volume":"86","author":"Pisani","year":"2014","journal-title":"Clin. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ymgme.2016.06.007","article-title":"Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry","volume":"119","author":"Hopkin","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1161\/STROKEAHA.110.579409","article-title":"Belgian Fabry study: Prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease","volume":"41","author":"Brouns","year":"2010","journal-title":"Stroke"},{"key":"ref_42","first-page":"1186","article-title":"Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease","volume":"53","author":"Eng","year":"1993","journal-title":"Am. J. Hum. Genet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","article-title":"Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy","volume":"105","author":"Sachdev","year":"2002","journal-title":"Circulation"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/BF03401993","article-title":"Twenty novel mutations in the alpha-galactosidase A gene causing Fabry disease","volume":"5","author":"Topaloglu","year":"1999","journal-title":"Mol. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13023-016-0473-4","article-title":"Multicenter Female Fabry Study (MFFS) - Clinical survey on current treatment of females with Fabry disease","volume":"11","author":"Lenders","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_46","unstructured":"Mehta, A., Beck, M., and Sunder-Plassmann, G. (2006). Fabry Disease: Perspectives from 5 Years of FOS, Oxford PharmaGenesis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: Baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_48","unstructured":"Mehta, A., Beck, M., and Sunder-Plassman, G. (2006). Fabry Disease: Perspectives from 5 Years of FOS, Oxford PharmaGenesis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","article-title":"The Mainz Severity Score Index: A new instrument for quantifying the Anderson\u2013Fabry disease phenotype, and the response of patients to enzyme replacement therapy","volume":"65","author":"Whybra","year":"2004","journal-title":"Clin. Genet."},{"key":"ref_50","unstructured":"National Kidney Foundation (2002). K\/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am. J. Kidney Dis., 39, S1\u2013S266."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0002-9149(86)90771-X","article-title":"Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings","volume":"57","author":"Devereux","year":"1986","journal-title":"Am. J. Cardiol."},{"key":"ref_52","unstructured":"Measuring Self-Reported Population Health: An International Perspective Based on EQ-5D. Available online: http:\/\/www.euroqol.org\/fileadmin\/user_upload\/Documenten\/PDF\/Books\/Measuring_Self-Reported_Population_Health_-_An_International_Perspective_based_on_EQ-5D.pdf."},{"key":"ref_53","first-page":"S79","article-title":"The Spanish version of EuroQol: A description and its applications. European Quality of Life scale","volume":"112","author":"Badia","year":"1999","journal-title":"Med. Clin. (Barc.)"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/17\/12\/1965\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:27:22Z","timestamp":1760210842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/17\/12\/1965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,24]]},"references-count":53,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,12]]}},"alternative-id":["ijms17121965"],"URL":"https:\/\/doi.org\/10.3390\/ijms17121965","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,24]]}}}